Changes

Jump to: navigation, search

Autoimmune cytopenia

116 bytes added, 22:09, 31 July 2017
m
Sirolimus (Rapamune) {{#subobject:35516b|Regimen=1}}
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
|-
|[httphttps://www.bloodjournalncbi.orgnlm.nih.gov/contentpmc/127articles/1PMC4705607/17.long Bride et al. 2015]
|style="background-color:#EEEE00"|Phase II
|-
|}
====Immunosuppressant therapy====*[[Sirolimus (Rapamune)]] 2 to 2.5 mg/m2/dayPO
**See manuscript for recommended dose adjustments
===References===
# Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [http://www.bloodjournal.org/content/127/1/17.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26504182 PubMed]
[[Category:Autoimmune cytopenia regimens]]
[[Category:Disease-specific pages]]
[[Category:Disease index]]
LookupUsers, editors, emailconfirmed
24,251
edits

Navigation menu